GSS Genetic Signatures Limited
Healthcare · Diagnostics & Research
· website
$0.06
52wk 0.05 – 0.43
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Genetic Signatures Limited
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$12.72M
P/E (trailing)
—
P/E (forward)
-0.86
EPS (trailing)
-0.05
Dividend yield
—
Payout ratio
0.0%
Beta
0.52
EV / EBITDA
1.53
Price / Book
0.29
ROE
-22.8%
Operating margin
-79.0%
Net margin
-56.5%
Total cash
$29.87M
Total debt
$559,000
Current ratio
8.98
Debt / Equity
0.01
Free cash flow
$-7.10M
Avg volume
533,296
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$15.90M
- Gross profit$7.78M
- Operating income-$18.48M
- Net income-$20.10M
- Diluted EPS-0.09
- Free cash flow-$13.19M
- Net debt-$6.68M